FDCDDQ
ZVRA icon

Federation des caisses Desjardins du Quebec’s Zevra Therapeutics ZVRA Stock Holding History

Federation des caisses Desjardins du Quebec’s Portfolio ZVRA Stock Details ZVRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.8K Sell
300
-50
-14% -$451 ﹤0.01% 2615
2025
Q4 		$3.14K Buy
350
+300
+600% +$2.84K ﹤0.01% 2535
2025
Q3 		$476 Buy
+50
New +$501 ﹤0.01% 2731

Other funds holding ZVRA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

Federation des caisses Desjardins du Quebec's ZVRA Position: Q1 2026 in Review

Federation des caisses Desjardins du Quebec reduced its Zevra Therapeutics (ZVRA) stake by 14% in Q1 2026, selling an estimated $451 and leaving 300 shares worth $2.8K. The position accounts for ﹤0.01% of the portfolio, ranked #2615.

Federation des caisses Desjardins du Quebec first reported a position in ZVRA in Q3 2025 and has held it in 3 quarters since. The position peaked at $3.14K in Q4 2025. 148 funds tracked by Wall St. Rank hold ZVRA as of Q1 2026.

  • Federation des caisses Desjardins du Quebec held 300 shares of Zevra Therapeutics worth $2.8K as of Q1 2026.
  • Federation des caisses Desjardins du Quebec sold 50 Zevra Therapeutics shares in Q1 2026, an estimated $451.
  • Zevra Therapeutics made up ﹤0.01% of Federation des caisses Desjardins du Quebec's portfolio in Q1 2026, its #2615 holding.
  • Federation des caisses Desjardins du Quebec first reported a position in Zevra Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • Federation des caisses Desjardins du Quebec's Zevra Therapeutics position peaked at $3.14K in Q4 2025.
  • 148 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q1 2026.

Based on Federation des caisses Desjardins du Quebec's 13F filing for Q1 2026, filed 14 May 2026.